Lipid Nanoparticles for Treatment of Psoriasis

In recent years, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are among the popular research topics for the delivery of lipophilic drugs. Although SLNs have demonstrated several beneficial properties as drug carrier, limited drug-loading and expulsion of drug during storage led to the development of NLCs. However, the superiority of NLCs over SLNs has not been fully established yet due to the contradictory results. In this study, SLNs and NLCs were developed using Clobetasol (CP) as model drug.

Autorentext

Dr. Ramesh Reddy. K. has done his Doctorate in Pharmaceutical Sciences at Jawaharlal Nehru Technological University Anantapur, He has been working as Associate Professor in Krishna Teja Pharmacy College, Tirupati, since 2012. He has been published Three Indian patents and 15 research papers published in reputed journals.